# Mohit Rawat

> Mohit Rawat is the Boston-based CEO of Myricx Bio, a UK-US biotech building a first-in-class antibody-drug conjugate platform based on NMT inhibition to treat cancer. He arrived in September 2025 fresh off Fusion Pharmaceuticals' $2.4 billion sale to AstraZeneca, where he was President and Chief Business Officer. With a Harvard MBA, an MIT chemical engineering master's, and stints at Novartis, AbbVie and McKinsey, he is steering Myricx toward its first human clinical trials in 2026.

- **Role:** Chief Executive Officer at Myricx Bio
- **Organizations:** Myricx Bio, Fusion Pharmaceuticals, Novartis, AbbVie, McKinsey & Company
- **Education:** MBA, Harvard Business School, MS, Chemical Engineering, Massachusetts Institute of Technology (MIT)
- **Known for:** Helped transform Fusion Pharmaceuticals into a commercially-focused organisation, leading to its $2.4 billion acquisition by AstraZeneca in 2024, Led M&A and business development/licensing transactions exceeding $5 billion in value, Helped bring forward asciminib (ABL001) toward approval as part of Novartis' $3 billion+ CML franchise

## Career timeline

- **Earlier career** — Leader in the biopharmaceutical practice at McKinsey & Company, advising on business development, R&D, commercialization and strategy
- **Pre-2017** — Asset team lead and senior director, immunology and neuroscience, at AbbVie
- **At Novartis** — Executive director for early-stage pipeline (NASH, cardiovascular, renal, metabolism); US marketing director for COSENTYX; VP and global disease lead for the $3B+ CML franchise including asciminib
- **2021** — Appointed President and Chief Business Officer of Fusion Pharmaceuticals
- **2024** — Fusion Pharmaceuticals acquired by AstraZeneca for $2.4 billion
- **2025** — Appointed CEO and Board member of Myricx Bio, effective September 22, 2025

## Achievements

- Helped transform Fusion Pharmaceuticals into a commercially-focused organisation, leading to its $2.4 billion acquisition by AstraZeneca in 2024
- Led M&A and business development/licensing transactions exceeding $5 billion in value
- Helped bring forward asciminib (ABL001) toward approval as part of Novartis' $3 billion+ CML franchise
- Led commercial and strategic efforts for COSENTYX, a Novartis product with more than $6 billion in sales
- Launched multiple specialty products in oncology and other therapeutic areas

## Latest updates

- **2025-09** — Appointed CEO and Board member of Myricx Bio, joining from Fusion Pharmaceuticals and expanding the company's leadership team across the US and UK.

## Links

- Website: https://myricxbio.com
- LinkedIn: https://www.linkedin.com/in/mohitrawat/

---

Profile page: https://yespress.io/mohit-rawat
Published by YesPress — https://yespress.io
Last updated: 2026-06-03